Globus Medical Announces Acquisition Of Higgs Boson Health To Transform Healthcare Experience Through Ai-Driven Digital Solutions

Globus Medical (GMED) announced its Excelsius3D imaging system received CE marking, allowing sales in the EU and UK. The system combines 3D cone-beam CT, 2D fluoroscopy, and digital radiography for surgical use. CEO Keith Pfeil highlighted the milestone's importance for the Excelsius Ecosystem. The company has been active in M&A and product development, including acquiring Higgs Boson Health and Nevro.

Globus Medical (GMED) received CE Mark approval for its Excelsius3D imaging system, allowing its commercial launch in the EU and UK. The approval expands the company's Excelsius platform into new markets, supporting advanced surgical procedures. Globus Medical, with a market cap of $10.5b, aims to integrate robotics, imaging, and implants for higher margins in spine and orthopaedic care.

Globus Medical (GMED) received CE mark for its Excelsius3D imaging system for spine and cranial procedures, enabling EU/UK commercialization. The system combines 3D CT, 2D fluoroscopy, and digital radiography, integrating with the ExcelsiusGPS robotic navigation system. According to the company, this expands its Excelsius ecosystem in Europe.

Globus Medical (GMED) received CE marking for its Excelsius3D imaging system, allowing commercial launch in the EU and UK. The system is part of the company's imaging and navigation platform for spine and orthopedic procedures. Globus Medical has a market cap of approximately $10.8 billion. The approval supports the company's strategy in surgical imaging and guidance platforms, potentially contributing to earnings and margin expansion.

Globus Medical (GMED) received CE Mark approval for its Excelsius3D imaging system, allowing commercial use in the EU and UK. The system combines 3D imaging, 2D fluoroscopy, and digital radiography, integrating with the company's ExcelsiusGPS robotic navigation system. GMED's stock closed at $78.12, up 2.41% in afterhours trading.

Globus Medical (GMED) shares rose 1% after-hours after receiving CE mark approval for its Excelsius3D imaging system in the EU and UK. The system integrates with the company's ExcelsiusGPS robotic navigation system and was previously cleared by the FDA in 2021. The company plans to commercialize the product in these markets.